Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#assertion>. }
Showing items 1 to 10 of
10
with 100 items per page.
- association type Statement assertion.
- association label "pomalyst is a thalidomide analogue indicated in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy 1 1 pomalyst in combination with dexamethasone is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy" assertion.
- association subject drugbank:DB08910 assertion.
- association predicate treats assertion.
- association object DOID_9538 assertion.
- association relation TreatmentIndication assertion.
- drugbank:DB08910 category Drug assertion.
- DOID_9538 category Disease assertion.
- association association_type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association provided_by NeuroDKG assertion.